Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03489525 · ClinicalTrials.gov registry record · Phase 1
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
NCT03489525 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 107 participants.
The verdict
NCT03489525, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, pharmacokinetics and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD \[in the absence of establishing the MTD\]) for single agent MEDI2228 in adult subjects with multiple myeloma who are either transplant ineligible or post autologous stem cell transplant and are relapsed/refractory.
Interventions
- BIOLOGICAL Dose Escalation, MEDI2228, ADC (antibody drug conjugate)
- BIOLOGICAL Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2018-05-08 |
| Est. Completion | 2022-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03489525
The ClinicalTrials.gov registry entry for NCT03489525 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dose Escalation, MEDI2228, ADC (antibody drug conjugate) is the first listed.
NCT03489525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03489525 about?
NCT03489525 is a clinical study titled "MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma". The purpose of this study is to assess the safety, pharmacokinetics and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD \[in the absence of establishing the MTD\]) for single agent MEDI2228 in adult subjects...
What is the current status of trial NCT03489525?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2018-05-08. Estimated completion is 2022-03-21.
What interventions are being tested in trial NCT03489525?
The interventions under investigation include: Dose Escalation, MEDI2228, ADC (antibody drug conjugate) (BIOLOGICAL), Dose Expansion, MEDI2228, ADC (antibody drug conjugate) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03489525?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.